Sessions are scheduled in local time (CEST)

Browsing Over 481 Presentations

Sort By
AstraZeneca - HR+ metastatic breast cancer – how do we stay ahead of a dynamic disease? (ID 22)

Q&A / discussion (ID 944)

Lecture Time
12:05 - 12:30
Session Name
AstraZeneca - HR+ metastatic breast cancer – how do we stay ahead of a dynamic disease? (ID 22)
Room
Munich Hall
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Lilly - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use? (ID 21)

Questions and take-home learnings (ID 939)

Lecture Time
12:15 - 12:30
Session Name
Lilly - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use? (ID 21)
Room
Hamburg Hall
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Speakers
  • Sara A. Hurvitz (Santa Monica, CA, United States of America)
  • Miguel Martin Jimenez (Madrid, Spain)
Lilly - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use? (ID 21)

Assessing risk of recurrence in HR-positive, HER2-negative early breast cancer (ID 935)

Lecture Time
11:35 - 11:45
Session Name
Lilly - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use? (ID 21)
Room
Hamburg Hall
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Speakers
  • Sara A. Hurvitz (Santa Monica, CA, United States of America)
  • Miguel Martin Jimenez (Madrid, Spain)
Novartis - Decision-making in a dynamic treatment landscape: Discussions on challenging patient cases in HR+/HER2- advanced breast cancer (ID 23)

Welcome and introductions (ID 945)

Lecture Time
11:30 - 11:35
Session Name
Novartis - Decision-making in a dynamic treatment landscape: Discussions on challenging patient cases in HR+/HER2- advanced breast cancer (ID 23)
Room
Frankfurt Hall
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Speakers
  • Sherko Kuemmel (Essen, Germany)
AstraZeneca - HR+ metastatic breast cancer – how do we stay ahead of a dynamic disease? (ID 22)

Introduction (ID 940)

Lecture Time
11:30 - 11:35
Session Name
AstraZeneca - HR+ metastatic breast cancer – how do we stay ahead of a dynamic disease? (ID 22)
Room
Munich Hall
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Speakers
  • Javier Cortés (Madrid, Spain)
Lilly - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use? (ID 21)

Impact of oral targeted adjuvant therapies in patients with HR-positive, HER2-negative early breast cancer (ID 936)

Lecture Time
11:45 - 11:55
Session Name
Lilly - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use? (ID 21)
Room
Hamburg Hall
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Speakers
  • Sara A. Hurvitz (Santa Monica, CA, United States of America)
  • Miguel Martin Jimenez (Madrid, Spain)
Novartis - Decision-making in a dynamic treatment landscape: Discussions on challenging patient cases in HR+/HER2- advanced breast cancer (ID 23)

First-line treatment in HR+/HER2- ABC: Patient cases (ID 946)

Lecture Time
11:35 - 12:00
Session Name
Novartis - Decision-making in a dynamic treatment landscape: Discussions on challenging patient cases in HR+/HER2- advanced breast cancer (ID 23)
Room
Frankfurt Hall
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Speakers
  • Sherko Kuemmel (Essen, Germany)
AstraZeneca - HR+ metastatic breast cancer – how do we stay ahead of a dynamic disease? (ID 22)

Reacting to a dynamic disease (ID 941)

Lecture Time
11:35 - 11:45
Session Name
AstraZeneca - HR+ metastatic breast cancer – how do we stay ahead of a dynamic disease? (ID 22)
Room
Munich Hall
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Speakers
  • Komal Jhaveri (New York, United States of America)
Lilly - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use? (ID 21)

Welcome and introductions (ID 934)

Lecture Time
11:30 - 11:35
Session Name
Lilly - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use? (ID 21)
Room
Hamburg Hall
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Speakers
  • Sara A. Hurvitz (Santa Monica, CA, United States of America)
  • Miguel Martin Jimenez (Madrid, Spain)
Novartis - Decision-making in a dynamic treatment landscape: Discussions on challenging patient cases in HR+/HER2- advanced breast cancer (ID 23)

Sequencing following progression after first-line CDK4/6i: Patient cases (ID 947)

Lecture Time
12:00 - 12:20
Session Name
Novartis - Decision-making in a dynamic treatment landscape: Discussions on challenging patient cases in HR+/HER2- advanced breast cancer (ID 23)
Room
Frankfurt Hall
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Speakers
  • Michelino De Laurentiis (Napoli, Italy)
AstraZeneca - HR+ metastatic breast cancer – how do we stay ahead of a dynamic disease? (ID 22)

Moving ahead of a dynamic disease (ID 942)

Lecture Time
11:45 - 11:55
Session Name
AstraZeneca - HR+ metastatic breast cancer – how do we stay ahead of a dynamic disease? (ID 22)
Room
Munich Hall
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Speakers
  • François Clément Bidard (Paris, France)
Lilly - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use? (ID 21)

Optimizing adherence and persistence with oral targeted adjuvant therapies in HR-positive, HER2-negative early breast cancer (ID 937)

Lecture Time
11:55 - 12:05
Session Name
Lilly - Targeted adjuvant strategies for HR-positive HER2-negative early breast cancer: Who can benefit, and how can we optimize their use? (ID 21)
Room
Hamburg Hall
Date
Thu, 11.05.2023
Time
11:30 - 12:30
Speakers
  • Sara A. Hurvitz (Santa Monica, CA, United States of America)
  • Miguel Martin Jimenez (Madrid, Spain)